CRISPR kills HIV and eats Zika 'like Pac-Man'. Its next target? Cancer.

http://www.wired.co.uk/article/crispr-disease-rna-hiv

Breast feeding reduces mother's future endometrial/uterine cancer risk.

http://www.abc.net.au/radionational/programs/...r-risk/8630730#transcript

More precise diagnostics for improved cancer outcomes

Researchers use supercomputers at the Texas Advanced Computing Center to design and test new tools for cancer detection

In the future, it may be possible to diagnose cancer much earlier using improved detection systems. Computing resources are helping researchers explore improved breast tissue mapping, nanopore and lab-on-a-chip biosensors, and cell-entering cancer detectors. Advanced computing is critical for the simulation and materials design aspects of these emerging diagnostic devices.

https://www.sciencedaily.com/releases/2017/06/170628131404.htm

Novel leukemia treatment could be 1st gene therapy

The Food and Drug Administration advisory panel voted 10-0 on Wednesday in favor of the leukemia treatment developed by the University of Pennsylvania and Novartis Corp. The FDA usually follows recommendations from its expert panels, but isn't obligated to do so.

http://abcnews.go.com/Health/wireStory/fda-ad...tential-1st-gene-48587970

On Thursday, August 3 @ 2-3pm ET, the American Chemical Society (ACS) will be conducting a free webinar entitled "Discovering Vismodegib in the Fight Against S... of the Hedgehog Pathway. " <Edit> Since the entire title didn't show up in the hyperlink, the title is "Discovering Vismodegib in the Fight Against Skin Cancer: The First Approved Inhibitor of the Hedgehog Pathway." </edit>

According to the American Cancer Society about 3 million Americans are detected with skin cancer each year with Basal Cell Carcinoma is the most common form of skin cancer found. Join Dan Sutherlin, a member of the team at Genentech who won the ACS Heroes of Chemistry Award, as he presents on the discovery of vismodegib. This is the first drug to be approved by the FDA for the treatment of advanced basal cell carcinoma (BCC), giving patients with locally advanced or metastatic BCC an important treatment where there were few to no options. Clinical results with this molecule in patients with inoperable BCCs have been dramatic with many reports of tumors shrinking to where no visible signs of cancer can be detected.

This is part of the Part Seven of the 2017 Industrial Science Series webinars, so if you have previously registered for the 2017 Drug Design and Delivery Symposium series, for which I often post webinar info, you'll probably need to register separately for this one. Click the link in the first paragraph for more info and registration information.